Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-13
2006-06-13
Fay, Zohreh (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S912000
Reexamination Certificate
active
07060695
ABSTRACT:
An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
REFERENCES:
patent: 5198460 (1993-03-01), Pandey et al.
patent: 5798349 (1998-08-01), Levy et al.
patent: WO 02/062384 (2002-08-01), None
patent: WO 02/062386 (2002-08-01), None
Michels, S. et al., “Changes in Neovascular Membranes and Normal Choroid Blood Vessels After Multiple Photodynamic Therapy Treatments!” Ophthalmologe 99(2):96-100 (2002).
Schmidt-Erfurth, U. et al., “Photodynamic Therapy with Verteporfin for Choroidal Neovascularization Caused by Age-Related Macular Degeneration: Results of Retreatmentsin a Phase 1 and 2 Study” Archives of Opthalmology 117(9):1177-1187 (1999).
Sickenberg, M. et al., “A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia Ocular Histoplasmosis Syndrome, Angioid Streaks, and Idiopathic Causes” Archives of Opthalmology 118(3):327-336 (2000).
Scott, L. et al., “Verteporfin.” Drugs & Aging 16(2):139-148 (2000).
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. “Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin” Arch. Opthalmol. 117: 1329-1345 (1999).
Azab Mohammad
Reaves, Jr. Troy Albert
Strong H. Andrew
Fay Zohreh
Morrison & Foerster / LLP
Novartis AG
QLT Inc.
LandOfFree
Method to prevent vision loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to prevent vision loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to prevent vision loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683668